Diminished Ovarian Reserve
Pipeline by Development Stage
Women's Health is a $989M market with mature, consolidated portfolios dominated by legacy hormone therapies and specialty oncology agents.
Key Trends
- Heavy concentration in estrogen receptor agonists and single-blockbuster dependency (INLYTA 47% of market)
- Multiple patent cliffs 2027-2030 creating near-term revenue pressure and consolidation risk
- Hiring concentrated in commercial and specialty recruitment, not R&D expansion
Career Verdict
Viable but cautious entry point—stable commercial roles available, but limited innovation pipeline and impending LOE events suggest a mature market in defensive posture rather than growth mode.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | INLYTA (axitinib) | Pfizer | $0.467B | 47% | Peak | Stable | 11.2yr |
| 2 | KORLYM (mifepristone) | Corcept Therapeutics | $0.229B | 23% | Peak | Stable | 12.2yr |
| 3 | LUPRON DEPOT (leuprolide acetate) | AbbVie | $0.129B | 13% | LOE Approaching | Declining | |
| 4 | ESTRING (estradiol) | Pfizer | $0.050B | 5% | LOE Approaching | Declining | |
| 5 | PREMPRO (conjugated estrogens/medroxyprogesterone) | Pfizer | $0.040B | 4% | LOE Approaching | Declining |
Drug Class Breakdown
single-product dominance (INLYTA)
concentrated in specialty reproductive health
legacy product with pending LOE pressure
fragmented across 17 products, majority LOE-approaching
minor indication-specific use
niche positioning, small market share
Career Outlook
StableWomen's Health is a mature, consolidated market where career growth is incremental rather than exponential. Pfizer and AbbVie control ~61% of spending via blockbuster and legacy products, creating stable but competitive commercial environments. Impending patent cliffs (2027-2030) and fragmented early-stage pipeline suggest cost containment and defensive strategy dominance over expansion, meaning fewer senior advancement slots and limited innovation-driven upside. Opportunity exists in specialty segments (fertility platforms, digital health, device innovation) outside traditional pharma.
Breaking In
Target specialty commercial roles (MSL, outcomes research) or non-traditional employers (Progyny, digital health startups, device firms) rather than incumbent pharma, which offers less differentiation for new entrants.
For Experienced Professionals
Experienced professionals should assess portfolio defensibility and patent cliff timing before joining a company; AbbVie and Pfizer offer scale but entail consolidation risk, while boutique firms (Corcept, Duchesnay) offer strategic leverage in niche areas.
In-Demand Skills
Best For
Hiring Landscape
Women's Health hiring totals 117 jobs, but data shows significant reporting gaps (many major companies report 0 jobs despite large portfolios). Visible hiring is concentrated in Viatris (40 jobs, likely manufacturing/supply chain post-spinoff), Progyny (29 jobs, fertility/reproductive benefits platform), and specialized device/diagnostics firms (GE HealthCare, Caldera Medical, Natera). Commercial roles dominate disclosed positions (65 of 109 departmental roles), with IT second (7 roles at $222K avg, reflecting digital health emphasis).
Top Hiring Companies
By Department
Commercial and specialty sales roles offer stable near-term opportunity, but modest average salary ($82K commercial) and portfolio maturity suggest limited high-growth compensation upside; IT roles offer premium but are scarce.
On Market (1)
Approved therapies currently available
Competitive Landscape
6 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Clinical Trials (5)
Total enrollment: 678 patients across 5 trials
Delayed Start to Ovarian Stimulation
Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve
Ovarian Function Following Intraovarian Injection of PRP
Effect of Electro-acupuncture on Women With Diminished Ovarian Reserve
Study of PRP in Women With Evidence of Diminished Ovarian Reserve
Related Jobs in Women's Health
Urology Gynecology Sales Representative - Future Opportunity
Territory Representative - Birmingham
Medical Science Liaison, Women's Health
Medical Director, Women’s Health - MFM
General Medicines, Commercial Director, Menopause
Scientist, Reproductive & Molecular Biology
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.